1. What is your name? What is your position?

2. What is the department/industry you are working for?

3. Are you working on Rheumatoid Arthritis or with Rheumatoid Arthritis patients?

4. Which therapy/combined therapies are you using / prescribing? (multiple choices possible)

  Only Infliximab (Remicade®) Adalimumab (Humira®) Golimumab (Simoni®) Etanercept (Enbrel®) Certolizumab (Cimzia®) Other

5. Which factors do you use to diagnose rheumatoid arthritis and / or follow the disease state?

  Always Sometimes Never
Rheumatoid factors
Anti-CCP2 Antibody test
Antinuclear antibody (ANA) test
Anti-keratin antibody (AKA) test
Vectra DA
LISA Tracker

6. To which purpose are you using it?

7. What are your criteria for choosing this /those test(s)?

8. If an easy, reliable monitoring test based on the dosage of soluble VE-cadherin in serum would be available to predict the responsiveness to biotherapies and / or the disease state in Rheumatoid Arthritis patients, would you consider using it?

9. If this test would be also an indicator of atherosclerosis in Rheumatoid Arthritis patients, how would you consider this test?

10. What is the main criteria you will look for using this new test?